Have any questions? 706-721-6582 or cts@augusta.edu
- An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis
Clinical Trial
An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis
The purpose of this research registry is to study the long-term safety of abatacept (Orencia©) and see what effects (good and bad) it has on your child and his/her JIA. Abatacept has already been approved by the FDA for treatment of Juvenile Idiopathic Arthritis (JIA).
Eligibility Criteria
- Diagnosis of JIA (any category). Age < 18 years at the time of enrollment.* Receiving abatacept at the time of enrollment as per the treating physician?s decision.* Parent or legally acceptable representative willing to participate in the study and sign the informed consent.
RESEARCH. INNOVATION. DISCOVERY.